When I last reviewed Copart (CPRT) in this September 16, 2023 post, it had just released its FY2023 results. On October 10, Copart announced that it is transforming the auction world with the acquisition of a majority interest in Purple Wave, an online heavy equipment auction company. Now that we have CPRT's Q1 2024 financial [...]
The time to invest in great companies is when they fall out of favour. Buy Thermo Fisher Scientific (TMO) while it faces short-term headwinds. I last reviewed TMO in this brief September 8 post. At the time, shares were reasonably valued at ~$514 based on earnings guidance. On October 25, however, TMO released its Q3 [...]
In my November 9 guest post at Dividend Power, I suggest investors buy Nike (NKE) stock when investor fear returns. Consumers in various global economies are feeling the effects of higher inflation and the higher interest rates central banks have been using to combat higher inflation. It remains to be seen the extent to which [...]
This post is in response to inquiries about recommended reading. Other recommendations will be provided at a later date. On May 25, 2016, the 'work thing' ended and I got my life back. This is when I made a commitment to exercise more regularly. I have kept that commitment and typically have daily ~2-hour high-intensity [...]
Chevron's (CVX) share price has slid from its early November 2022 ~$190 peak to ~$147 following the release of its Q3 2023 report that showed rising expenses from overseas projects, most notably in Kazakhstan. The world, however, needs energy and CVX is positioning itself to play a key role in helping meet the world's future [...]
I last reviewed S&P Global (SPGI) in my July 29 post following the release of Q2 and YTD2023 results on July 27. With the release of Q3 and YTD2023 results and revised FY2023 guidance on November 2, I revisit this existing holding. Business Overview Please read Part 1 - Item 1 - Business in the [...]
In my August 3 Paycom Software (PAYC) post, I disclosed a new 200-share position in one of the 'Core' accounts within the FFJ Portfolio. I subsequently made a 50-share purchase on August 3 and another 50-share purchase on September 20. Fast forward to October 31 after the market close and PAYC released its Q3 and [...]
This FFJ Portfolio - October 2023 report is an overview of my recent investment activity. Fortunately, we have recently experienced a broad pullback which has resulted in an improvement in the valuation of many companies. Some investors may be disheartened by a drop in the value of their investment holdings. We must remember, however, that [...]
I last reviewed Fortive (FTV) in this July 31, 2023 post at which time I concluded that shares were fairly valued. Rather than add to my exposure, I expressed my interest in increasing exposure to companies facing short-term headwinds which appeared to have temporarily fallen out of favour with investors. Following a ~16% share price [...]
I last reviewed CME Group (CME) in this August 1, 2023 post at which time the most recently available financial information was for Q2 and YTD2023. With the release of Q3 and YTD2023 results on October 25, I revisit this holding. Overview A high-level overview of the company is provided in previous posts that are [...]